Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma

Next Previous
X
Search
Trial Profile

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Sirexatamab (Primary)
  • Indications Carcinoma; Endometrial cancer; Gynaecological cancer; Ovarian cancer; Sarcoma; Uterine cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Leap Therapeutics

    • Most Recent Events

    • 29 Mar 2023 Results of a phase 2 basket study in women with recurrent endometrial carcinoma published in the Gynecologic Oncology
    • 09 Sep 2021 Status changed from active, no longer recruiting to completed.
    • 14 May 2021 According to a Leap Therapeutics media release, results from this study presented in Leap Therapeutics financial media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top